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Abstract Systemic nitroglycerin (NTG) produces spon-
taneous-like migraine attacks in migraine sufferers and
induces a condition of hyperalgesia in the rat 4 h after
its administration. Endocannabinoid system seems to be
involved in the modulation of NTG-induced hyperalgesia,
and probably, in the pathophysiological mechanisms of
migraine. In this study, the analgesic effect of anandamide
(AEA) was evaluated by means of the formalin test, per-
formed in baseline conditions and following NTG-induced
hyperalgesia in male Sprague–Dawley rats. AEA was
administered 30 min before the formalin injection. In
addition, the effect of AEA (administered 30 min before
NTG injection) was investigated on NTG-induced Fos
expression and evaluated 4 h following NTG injection.
AEA induced a signiﬁcant decrease in the nociceptive
behavior during both phases of the formalin test in the
animals treated with vehicle, while it abolished NTG-
induced hyperalgesia during the phase II. Pre-treatment
with AEA signiﬁcantly reduced the NTG-induced neuronal
activation in nucleus trigeminalis caudalis, conﬁrming the
results obtained in our previous study, and in area pos-
trema, while the same treatment induced an increase of Fos
expression in paraventricular and supraoptic nuclei of the
hypothalamus, parabrachial nucleus, and periaqueductal
grey. The study conﬁrms that a dysfunction of the endo-
cannabinoid system may contribute to the development of
migraine attacks and that a pharmacological modulation of
CB receptors can be useful for the treatment of migraine
pain.
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Introduction
Alterations in the endocannabinoid levels have been found
in animal models of pain, neurological and neurodegener-
ative states, disorders and inﬂammatory conditions [1, 2].
There is strong evidence that cannabinoids (CB) can induce
antinociceptive effects in models of phasic or tonic pain,
through activation of CB receptors located on neurons both
within and outside the brain and spinal cord [3]. It has been
shown that CB suppress spinal Fos expression, a neuro-
chemical marker of neuronal activation [4], in a variety of
animal models of persistent pain [5, 6]. The role of the
endocannabinoid system in the pathogenesis of headaches
has been recently put under scrutiny. Migraine may be
caused by cerebral vasodilatation or by abnormal neuro-
logical ﬁring or by neurogenic dural inﬂammation [7].
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vasculaturecontaincalcitoningene-relatedpeptide(CGRP),
substance P and neurokinin [8]. Endocannabinoid deﬁ-
ciency has been hypothesized to underlie the pathophysi-
ology of migraine and several clinical studies [9] support
this idea although biochemical studies providing a scien-
tiﬁc basis for the potential efﬁcacy of (endo)cannabinoids
in migraine are really limited. In a previous study, it was
reported that anandamide (AEA), an endogenous ligand to
the CB receptor, inhibits CGRP-induced and nitric oxide
(NO)-induced neurogenic dural vasodilatation, suggesting
that AEA may be tonically released to modulate the
trigeminovascular system [10]. Theoretically, the reduction
of AEA levels, and thus the reduced inhibitory effect of
endocannabinoid system (ECS), may contribute to facili-
tate/maintain central sensitization in chronic head pain,
therefore providing an additional mechanism which con-
tributes to CGRP release and NO production [11, 12].
Systemic administration of nitroglycerin (NTG), a NO
donor, provokes spontaneous-like migraine attacks in
migraine sufferers. NTG also induces a condition of
hyperalgesia in the rat, through the activation of spinal and
brainstem structures involved in nociception [13–15]; As
such, NTG has been extensively used to investigate the
neurobiological correlates of migraine pain, in rodents
[13–15]; Recently, we have shown that NTG-induced
hyperalgesia is associated with an alteration of ECS in
some areas of rat brain [16]. In the mesencephalon, an
increased activity of both the hydrolases that are involved
in degradation of the 2-arachidonoylglycerol (2-AG) and
AEA, fatty acid amide hydrolase (FAAH) and monoacyl-
glycerol lipase (MAGL), has been observed, together with
an increased density of CB binding sites in the mesen-
cephalon. In the hypothalamus, NTG caused an increase in
the activity of FAAH associated with an increase in den-
sity of CB binding sites, while, in the medulla only the
activity of FAAH was increased [16]. In the present study
we have investigated the possible role for AEA in the
mechanisms mediating NTG-induced hyperalgesia in the
formalin test, a well-established model of persistent
somatic pain widely used in rats [17]. Additionally, we
evaluated the effect of AEA on the cerebral expression of
Fos protein elicited by NTG-induced hyperalgesia.
Materials and methods
Adult male Sprague–Dawley rats, weighing 180–220 g,
were used in the present investigation. Rats were randomly
divided in groups formed by 4–6 animals each, and
underwent the following experimental protocols.
Drugs
AEA (Sigma), suspended in 4% Tween 80, was injected
i.p. at a dose of 20 mg/kg, 30 min before the execution of
the formalin test (see below). This dose was chosen based
on the paper published by Jaggar et al. [18], where it was
demonstrated that AEA (dose range 5–25 mg/kg) reduces
the nociceptive behavior in the second phase of the for-
malin test. The 30-min interval, between AEA adminis-
tration and the formalin test, was chosen on the basis of
preliminary experiments showing a maximum antinoci-
ceptive effect for AEA at that time (data not shown).
AEA reduced ambulatory and non-ambulatory activities
(rearing and grooming) and body temperature was signiﬁ-
cantly decreased by the dose utilized, as reported in a
previous study [19].
Nitroglycerin (Astra Company, Italy), dissolved in sal-
ine alcohol and propylene glycol, was injected i.p. at a dose
of 10 mg/kg.
Behavioral response to formalin test
The formalin test is a well-established rat model of per-
sistent somatic pain. Following injection of 100 llo f1 %
formalin into the plantar surface of the right hind paw, the
animals were placed, one at a time, in a plexiglas obser-
vation chamber (10 9 20 9 24 cm) in which a mirror
(angled at 45) allowed unimpeded observation of the
animal’s paws. The total number of ﬂinches/shakes per min
was counted during the period from 1 to 5 min after
injection (phase 1) and, subsequently, for 1-min periods at
5-min intervals during the period from 15 to 60 min (phase
2) after formalin injection. Flinches/shakes, characterized
as a rapid and brief withdrawal or ﬂexion of the injected
paw, were readily identiﬁed. Incomplete formalin injection
constituted an exclusion criterion for the study. The anal-
gesic effect of AEA was evaluated by comparing the
response to the formalin test of AEA-treated versus
untreated rats, in basal conditions and following NTG
administration (4 h after the administration).
Experimental groups
– Control (for NTG4 h): i.p. injection of saline 4 h before
the formalin test;
– NTG4 h: i.p. injection of NTG 4 h before the formalin
test;
– AEA ? NTG4 h: i.p. injection of NTG (4 h before the
formalin test) and administration of AEA 30 min
before the formalin test;
– AEA: i.p. injection of AEA 30 min before the formalin
test;
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(vehicle) 30 min before the formalin test.
Fos immunohistochemistry
Animals were anaesthetized and perfused transcardially
with saline and ice-cold 4% paraformaldehyde 4 h after
NTG/saline administration. Brains were removed, post-
ﬁxed for 12 h in the same ﬁxative and subsequently
transferred in solutions of sucrose at increasing concen-
trations (up to 30%) during the following 72 h. Brains were
cut at 50 lm on a freezing sliding microtome. Fos
expression in the rat brain was detected by means of the
immunohistochemical technique with a rabbit polyclonal
antiserum directed against Fos protein (residues 4–17 of
human Fos). Tissue sections were incubated for 48 h at 4C
with the Fos antibody (Oncogene). After thorough rinsing
in buffer, sections were processed with the avidin biotin
technique, using a commercial kit. Cells positively stained
for Fos were visualized with nickel-intensiﬁed 30,30-diam-
inobenzidine tetra hydrochloride (DAB). After staining,
sections were rinsed in buffer, mounted onto glass slides,
air-dried and coverslipped.
Experimental groups
– NTG4 h: i.p. injection of saline 30 min before the NTG
administration;
– Control (for NTG4 h): i.p. injection of saline 30 min
before the saline administration;
– AEA ? NTG4 h: i.p. injection of AEA, 30 min before
the NTG administration;
– AEA: i.p. injection of AEA, 30 min before the saline
administration;
– Control (for AEA): i.p. injection of 4% Tween 80
(vehicle) 30 min before the saline administration.
Statistical evaluation
In the formalin test, the total number of ﬂinches/shakes
evoked by formalin injection was counted in phases I and II
of the formalin test, as described above. Differences
between groups were analyzed by Student’s t test and a
probability level of\5% was regarded as signiﬁcant.
For Fos expression, cell counts of individual nuclei were
made from every sixth section throughout their rostrocau-
dal extent for each rat and its control. In order to avoid
differences related to the asymmetrical sectioning of the
brain, Fos-positive cells were counted bilaterally (3 sec-
tions for each nucleus) (Scion Image Analysis) and the
mean value obtained from the two sides was used for the
statistical analysis. Student’s t test for unpaired data was
used to compare differences in the mean number of Fos-
immunoreactive nuclei per cell group between controls and
treatment groups. A probability level of\5% was regarded
as signiﬁcant.
Results
Anandamide and nitroglycerin-induced hyperalgesia
at formalin test
In the control group (for AEA), the injection of formalin
resulted in a highly reliable, typical, biphasic pattern of
ﬂinches/shakes of the injected paw, being characterized by
an initial acute phase of nociception within the ﬁrst 5 min,
followed by a prolonged tonic response from 15 to 60 min
after formalin injection. AEA administration signiﬁcantly
reduced the nociceptive behavior in both phases of the
formalin test (Fig. 1). NTG administration signiﬁcantly
increased the total number of ﬂinches/shakes in phase II
of formalin test, conﬁrming previous reports [14, 15].
AEA pre-treatment signiﬁcantly inhibited the nociceptive
behavior induced by NTG administration during phase II of
the test (Fig. 2).
Fig. 1 Effect of anandamide (AEA) treatment on hyperalgesia at the
formalin test. Pre-treatment with AEA, 30 min before vehicle
administration, signiﬁcantly decreases the total number of ﬂinches/
shakes during phase I and II. *p\0.05 versus control group. Data
were expressed as mean ± SD
Fig. 2 Effect of anandamide (AEA) pre-treatment on nitroglycerin-
induced hyperalgesia at the formalin test. Pre-treatment with AEA,
30 min before nitroglycerin (NTG) administration, signiﬁcantly
decreases the total number of ﬂinches/shakes during phase II.
*p\0.05 versus NTG4 h group. Data were expressed as mean ± SD
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123Anandamide and Fos expression in the animal model
of migraine
In agreement with our previous ﬁndings [20, 21, 22], NTG
administration induced neuronal activation in paraventric-
ular (PVH) and supraoptic nuclei (SON) of the hypothal-
amus, central nucleus of the amygdala (CEA), ventrolateral
column of the periaqueductal grey (PAG), parabrachial
nucleus (PBN), locus coeruleus (LC), nucleus tractus sol-
itarius (NTS), area postrema (AP) and nucleus trigeminalis
caudalis (NTC). Pre-treatment with AEA signiﬁcantly
reduced the NTG-induced neuronal activation in NTC,
conﬁrming the results obtained in our previous study [16],
and in AP, while the same treatment induced an increase of
Fos expression in PVH, SON, PAG, PBN (Figs. 3, 4, 5). It
is noteworthy that AEA administration per se increased
signiﬁcantly Fos expression in PVH, SON, PAG and PBN
(Fig. 6), conﬁrming previous studies. Indeed, when AEA
and AEA ? NTG groups were compared no differences
were seen with regard to Fos expression in these latter
nuclei.
Discussion
Anandamide and nitroglycerin-induced hyperalgesia
NTG activates speciﬁc cerebral nuclei and induces hyper-
algesia through the intervention of selected neurotrans-
mitters and neuromediators, with a speciﬁc time-pattern in
rats [14, 15]. Endocannabinoid receptors have been iden-
tiﬁed in many of the NTG-activated areas [23, 24]. AEA
induced a signiﬁcant decrease in the nociceptive behavior
during both phases of the formalin test in the animals
treated with vehicle; furthermore, AEA abolished NTG-
induced hyperalgesia in phase II of formalin test. These
results are in accordance with previous observations
showing that AEA, in the range of 10–100 mg/kg, has
Fig. 3 Pretreatment with anandamide (AEA) induced a signiﬁcant
increase of nitroglycerin-induced neuronal activation in several brain
nuclei, which include paraventricular (PVH) and supraoptic nuclei
(SON) of the hypothalamus, parabrachial nucleus (PAB), periaqu-
eductal grey (PAG). By contrast, AEA induced a signiﬁcant decrease
of Fos expression in the nucleus trigeminalis caudalis (NTC) and
area postrema (AP). *p\0.05 versus NTG4 h group. Data were
expressed as mean ± SD
Fig. 4 Micrographs of
representative sections of the
paraventricular nucleus of
hypothalamus (PVH) of rats
treated with nitroglycerin (a)o r
pre-treated with anandamide
(AEA) before receiving
nitroglycerin (b), or treated with
saline (c) or AEA (d)
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123analgesic effects in hyper-acute somatic nociceptive mod-
els, such as the tail-ﬂick and hot-plate tests [25, 26].
The mechanisms and targets underling the AEA-med-
iated modulation of NTG-induced hyperalgesia are not
clearly understood. The anti-hyperalgesic effect of AEA
observed in the formalin test could be localized at the
spinal and supraspinal level. It was demonstrated that the
antinociceptive effects of D
9-tetrahydrocannabinol (D
9-
THC) in the tail-ﬂick test are attenuated following spinal
transection, showing that also supraspinal sites may play
an important role in CB antinociceptive action [27].
Another study showed that microinjection of CB agonists
into the dorsolateral PAG produce antinociception [28].
CB1 receptors are localized on ﬁbers in the spinal tri-
geminal tract and in the NTC [6]. Therefore, it is also
possible that AEA exerts a direct effect upon trigeminal
neurons [10] to cause inhibition of CGRP release from
central terminals of primary afferent ﬁbers, and to reduce
the nociceptive behavior. NTG induces CGRP release
from NTC for a period of 4 h after its administration,
while formalin injection induces an ipsilateral decrease in
CGRP in the NTC 1 h later [29, 30]. AEA interacts
mainly with CB1 receptors [31], although CB2 receptors
located in the lower brainstem may also be involved [32,
33]. In line with this idea, it was shown that selective
activation of CB2 receptors suppresses spinal Fos protein
expression and pain behavior in a rat model of inﬂam-
mation [5].
Anandamide and Fos expression in the animal model
of migraine
The present investigation shows AEA-induced Fos immu-
noreactivity in a wide variety of cerebral nuclei, whose
distribution is similar to previous studies by other groups
[34, 35]. Pre-treatment with AEA selectively inhibited
NTG-induced Fos expression, in the NTC and AP, areas
involved in the generation and modulation of migraine
pain. No deﬁnite conclusion can be drawn with regard to
the effect of AEA on the other nuclei that are known to be
activated by NTG (PVH, SON, PAG, and PBN) because
Fig. 5 Micrographs of
representative sections of the
nucleus trigeminalis caudalis
and area postrema of rats treated
with nitroglycerin (NTG)
(a–c) or pre-treated with
anandamide (AEA) before
receiving NTG (b–d). AP area
postrema, NTC nucleus
trigeminalis caudalis
Fig. 6 Anandamide administration induces a signiﬁcant increase of
Fos expression in several brain nuclei, which include paraventricular
(PVH) and supraoptic nuclei (SON) of the hypothalamus, parabra-
chial nucleus (PAB) and periaqueductal grey (PAG). *p\0.05
versus control group. Data were expressed as mean ± SD
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123AEA per se induces an intense Fos expression in these
structures that outweighs NTG-induced Fos expression.
The ﬁnding regarding the inhibition of NTG-induced Fos
expressionintheNTCandAPseemsparticularlyrelevantfor
the role of AEA in migraine. With regard to NTC, activation
of CB receptors may inﬂuence trigeminovascular neuronal
ﬁring byreducingexpressionofFosprotein, assuggestedby
ourpreviousstudy[16].Indeed,CB1receptorsareexpressed
alsoonaxonterminalsofprimarysensoryneurons,i.e.inthe
nociceptive areas of spinal cord, DRG and trigeminal gan-
glia,andtheirexpressionispartiallyco-localizedwithCGRP
and substance P [3]. AEA is capable of inhibiting capsaicin-
evoked CGRP release from terminals of primary afferent
ﬁbers of spinal cord to modulate neurotransmitters release
[36]. Our results are in agreement with data obtained in
another animal model of migraine, where it was shown that
activation of CB1 receptor reduces Fos immunoreactivity
induced after activation of the ophthalmic division of the
trigeminal nerve, in neurons of the NTC [37]. Additionally,
AEA might inhibit neuronal activation in the NTC also via
CB2 receptors [32]. Also the inhibitory effect of AEA in AP
is relevant for migraine, when considering that nausea and
vomiting are the most frequently accompanying symptoms
of migraine pain. AP indeed is an important area for the
control of autonomicfunctions. Our results are in agreement
with data from Van Sickle et al. [33] that have reported a
reduction of Fos expression induced by emetic stimuli in the
AP following D
9-THC administration. CB1 receptors play a
more important role in the brainstem, as compared to VR1
receptors, in the control of emesis, indicating that endoge-
nously released endocannabinoids/endovanilloids inhibit
emesis preferentially via CB1 receptors [37].
Conclusions
The anti-nociceptive effect of AEA on NTG-induced
hyperalgesia is unequivocally demonstrated in this study,
and it seems that the exact localization of this effect is the
NTC. Furthermore, AEA inhibits the effect of NTG on AP,
the emetic area par excellence.
By combining our data with the ﬁndings available from
the literature, we can hypothesize that a dysfunction of the
endocannabinoid system may contribute to the develop-
ment of migraine attacks and that a speciﬁc pharmaco-
logical modulation of CB1 and CB2 receptors may be
useful for the treatment of migraine pain, without delete-
rious effects, as well as of speciﬁc associated symptoms
(nausea, in primis).
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